Clinical profile of pain in post-COVID-19 patients: systematic review
Perfil clínico da dor em pacientes no pós-COVID-19: revisão sistemática
Pammela Weryka da Silva Santos; Abrahão Fontes Baptista; Thalyta Cibele Passos dos Santos; Fuad Ahmad Hazime
Abstract
BACKGROUND AND OBJECTIVES: Although research shows that pain is more frequent during COVID-19 infection, little is known about the characterization of pain and factors that influence its permanence after infection. Therefore, the objective of this study was to describe the clinical profile of pain in post-COVID-19 patients.
CONTENTS: This is a systematic review conducted in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) recommendations. Articles were searched from November 2021 to November 2022 in the Pubmed, Embase, Web of Science, Scopus, Cochrane and PsycINFO databases. Five observational studies were included for qualitative synthesis. There was an increase in the intensity of pain in all regions of the body during the infection when compared to the pre-infection state, remaining after the infection. The most reported post-COVID-19 pains are: neuropathic pain, generalized pain and pain in the cervical region. The average duration of post-COVID-19 pain was six months.
CONCLUSION: There is persistence of pain after infection with the new coronavirus, with the presence of “new pain” and “new chronic pain”, and the worsening of pain in specific groups that had COVID-19.
Keywords
Resumo
JUSTIFICATIVA E OBJETIVOS: Embora as pesquisas evidenciem o quadro álgico mais frequente durante a infecção da COVID-19, pouco se sabe sobre a caracterização da dor e fatores que influenciam sua permanência após a infecção. Portanto, o objetivo deste estudo foi descrever o perfil clínico de dor em pacientes pós-COVID-19.
CONTEÚDO: Trata-se de uma revisão sistemática conduzida conforme as recomendações Preferred Reporting Items for Sistematic reviews and Meta-Analyses (PRISMA). Os artigos foram pesquisados no período de novembro de 2021 a novembro de 2022, no banco de dados Pubmed, Embase, Web of Science, Scopus, Cochrane e PsycINFO. Foram incluídos cinco estudos observacionais para síntese qualitativa. Evidenciou-se um aumento da intensidade da dor em todas as regiões do corpo durante a infecção quando comparado com o estado pré-infecção, mantendo-se após a infecção. As dores mais relatadas pós-COVID-19 foram dor neuropática, dor generalizada e dor na região cervical. A média de tempo da dor no pós-COVID-19 foi de seis meses.
CONCLUSÃO: Há persistência da dor após infecção pelo novo coronavírus, com a presença de “dor nova” e “dor crônica nova”, e a piora da dor em grupos específicos que tiveram COVID-19.
Palavras-chave
References
1 Santos-Pinto CD, Miranda ES, Osorio-de-Castro CG. O “kit-covid” e o Programa Farmácia Popular do Brasil. Cad Saude Publica. 2021;37(2):e00348020.
2 Li L, Sun W, Han M, Ying Y, Wang Q. A study on the predictors of disease severity of COVID-19. Med Sci Monit 2020;26:e927167.
3 Ozkan H, Ambler G, Banerjee G, Chan E, Browning S, Mitchell J, Perry R, Leff AP, Simister RJ, Werring DJ; SIGNaL collaborators. The impact of the UK COVID-19 pandemic on patient-reported health outcomes after stroke: a retrospective sequential comparison. J Neurol. 2022;269(4):1741-50.
4 Çalıca Utku A, Budak G, Karabay O, Güçlü E, Okan HD, Vatan A. Main symptoms in patients presenting in the COVID-19 period. Scott Med J. 2020;65(4):127-32.
5 Moradali MR, Simbar M, Roozbahani S, Koochaksaraei FY, Hosseinzadeh P, Zareipour MA, Bayat F, Amighi M, Shahrahmani H. Epidemiologia, prevenção e estratégias de controle do coronavírus COVID 19 no Irã: uma revisão sistemática. Maced J Med Sci. 2020;8(T1):480-8.
6 Wang VC, Mullally WJ. Pain neurology. Am J Med. 2020;133(3):273-80.
7 Parizad N, Goli R, Faraji N, Mam-Qaderi M, Mirzaee R, Gharebaghi N, Baghaie R, Feizipour H, Haghighi MM. Effect of guided imagery on anxiety, muscle pain, and vital signs in patients with COVID-19: A randomized controlled trial. Complement Ther Clin Pract. 2021;43:101335.
8 Dalewski B, Palka L, Kiczmer P, Sobolewska E. The Impact of SARS-CoV-2 Outbreak on the polish dental community’s standards of care-a six-month retrospective survey-based study. Int J Environ Res Public Health. 2021;18(3):1281.
9 de Miranda DAP, Gomes SVC, Filgueiras PS, Corsini CA, Almeida NBF, Silva RA, Medeiros MIVARC, Vilela RVR, Fernandes GR, Grenfell RFQ. Long COVID-19 syndrome: a 14 months longitudinal study during the two first epidemic peaks in Southeast Brazil. Trans R Soc Trop Med Hyg, 2022;116(11):1007-14.
10 Castro APCR, Nascimento JS, Palladini MC, Pelloso LRCA, Barbosa MHL. Dor no paciente com síndrome pós-COVID-19. Rev Cient HSI. 2021;5(2):55-62.
11 Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372(n71):1-9.
12 Joanna Briggs Institute. Checklist for Systematic Reviews and Research Syntheses Critical Appraisal Checklist for Systematic Reviews and Research Syntheses 2 [Internet]. 2017. Available from:
13 Shiwa SR, Costa LOP, Costa LCM, Moseley A, Hespanhol Junior LC, Venâncio R, Ruggero C, Sato TO, Lopes AD. Reproducibility of the Portuguese version of the PEDro Scale. Cad Saude Pública. 2011;27(10):2063-7.
14 Şahin T, Ayyildiz A, Gencer-Atalay K, Akgün C, Özdemir HM, Kuran B. Pain symptoms in COVID-19. American J Phys Med Rehabil. 2021;100(4):307-12.
15 Soares FHC, Kubota GT, Fernandes AM, Hojo B, Couras C, Costa BV, Lapas JDDS, Braga LM, Almeida MM, Cunha PHMD, Pereira VHH, Morais ADS, Teixeira MJ, Ciampi de Andrade D. Prevalence and characteristics of new-onset pain in COVID-19 survivors, a controlled study. Eur J Pain. 2021;25(6):1342-54.
16 Bilgin A, Kesik G, Özdemir L. Biopsychosocial factors predicting pain among individuals experiencing the novel coronavirus disease (COVID-19). Pain Manag Nurs. 2022;23(1):79-86.
17 Büyükşireci DE, Türk AÇ, Erden E, Erden E. Evaluation of pain, disease activity, anxiety, depression, and neuropathic pain levels after COVID-19 infection in fibromyalgia patients. Ir J Med Sci. 2023;192(3):1387-93.
18 Herrero-Montes M, Fernández-de-las-Peñas C, Ferrer-Pargada D, Tello-Mena S, Cancela-Cilleruelo I, Rodríguez-Jiménez J, Palacios-Ceña D, Parás-Bravo P. Prevalence of neuropathic component in post-COVID pain symptoms in previously hospitalized COVID-19 survivors. Int J Clin Pract. 2022;16;2022:3532917.
19 Ota LS, Nakamatsu AP, Alves EO, Fré GGP, Trevisan IB. Pós-COVID-19: sintomas persistentes e sua relação com o nível de fadiga. Res Soc Develop. 2023;12(2):e27312240235.
20 Pereira JI, Afonso RM, Reis-Pina P. Impact of the COVID-19 pandemic on the non-cancer chronic pain and its management in the elderly. BrJP. 2022;5(3):285-93.
21 Dalewski B, Palka L, Kiczmer P, Sobolewska E. The Impact of SARS-CoV-2 Outbreak on the polish dental community’s standards of care-a six-month retrospective survey-based study. Int J Environ Res Public Health. 2021;18(3):1281.
Submitted date:
02/09/2023
Accepted date:
06/21/2023
Facebook
Google+
Twitter
LinkedIn
Mendeley
Email